REST, not REST4, is a risk factor associated with radiotherapy plus chemotherapy efficacy in glioma
Authors Li C, Zou H, Wang ZF, Tang X, Fan X, Zhang K, Liu J, Li Z
Received 5 January 2018
Accepted for publication 27 March 2018
Published 22 May 2018 Volume 2018:12 Pages 1363—1371
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Qiongyu Guo
Cuilin Li,1,2 Hecun Zou,1–3 Zhifei Wang,4 Xinyue Tang,1,2 Xitang Fan,4 Ke Zhang,1,2 Jianqiu Liu,1,2 Zhi Li1,2
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China; 2Institute of Clinical Pharmacology, Central South University and Hunan Key Laboratory of Pharmacogenetics, Changsha, China; 3Institute of Life Sciences, Chongqing Medical University, Chongqing, China; 4Department of Neurosurgery, Third Xiangya Hospital of Central South University, Changsha, China
Background/aim: Repressor element silencing transcription factor (REST) is a transcription repressor, expressed in several malignancies. This study aims to evaluate the prognostic values of REST and its splicing variant REST4 in glioma, and investigate the potential correlation between REST and REST4.
Methods: REST and REST4 expression values were evaluated by qRT-PCR in 89 patients with gliomas and 10 with normal brain tissues.
Results: Upregulation of REST was related to higher World Health Organization (WHO) grade, larger tumor size, higher ki67, and higher p53 positive rate. After radiotherapy+temozolomide (RT+TMZ) treatment, low REST expression patients could get better therapeutic efficacy (P=0.031). The positive rate of REST4 expression was only 13.5% in glioma tissues, and REST4 expression was not associated with clinical characteristics and REST expression in this study.
Conclusions: REST was a prognostic factor in glioma, while REST4 was not. REST expression can be a predictor in evaluating the survival outcome of gliomas patients treated with RT+TMZ after surgery.
Keywords: REST, REST4, glioma, radiotherapy, chemotherapy, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]